SpectraCure has submitted a new patent application to the European Patent Office. The patent application regards the technical solution used in the new generation of SpectraCure's treatment system. The technology makes it possible to use the same optical fiber for both treatment and dose monitoring; together with the IDOSE software, this is what makes the SpectraCure method unique.
In SpectraCure's existing system, the same functionality is achieved by means of a motor-driven fiber-optical switch. By contrast, the novel technology covered by the patent application uses only fixed components, which drastically reduces the size and complexity of the system. In addition, the manufacturing cost is decreased by at least three quarters, less maintenance is required, and several technical performance parameters are improved.
– The new solution will be at the heart of SpectraCure's product on the market. The patent entails that we secure protection for the technology for a long time to come, since the novel solution is so technically and economically superior to the old, says Johannes Swartling, CTO of SpectraCure.
The new technology is the result of several years of development work, and partially derives from new developments in laser technology, optics and measurement technology, and from new types of components becoming available.
The patent application has first been submitted to the European Patent Office for review. The application will then move into an international phase to get approval on all the major world markets.
For more information, please contact:
SpectraCure AB (publ), CEO, Masoud Khayyami, telephone: +46(0) 70 815 21 90
Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se
telephone: +46(0) 8 503 000 50
See also: www.spectracure.com
